Warfarin and cancer

New York, June 30, 2000 (Praxis Press) - The incidence of cancer increases after the diagnosis of venous thromboembolism, which is usually treated with vitamin K antagonists such as warfarin. Few randomized trials have examined the relation between the development of metastases and the clotting mechanism. During a prospective, randomized study that lasted eight years, Schulman and Lindmarker have compared the effects on the incidence of cancer of a six-week and a six-month warfarin treatment giv


Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

New York, June 30, 2000 (Praxis Press) - The incidence of cancer increases after the diagnosis of venous thromboembolism, which is usually treated with vitamin K antagonists such as warfarin. Few randomized trials have examined the relation between the development of metastases and the clotting mechanism. During a prospective, randomized study that lasted eight years, Schulman and Lindmarker have compared the effects on the incidence of cancer of a six-week and a six-month warfarin treatment given to patients after a first episode of venous thromboembolism (see paper). The study shows that while the incidence of cancers is higher during the first two years -- overall ratio of 3.4 -- it is lower in the patients who received the six-month warfarin treatment, 10.3 percent vs. 15.8 percent. The study strongly suggests that warfarin has an antineoplastic effect, although its mechanism is still unknown. While such data are too scarce to justify ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo